Rare Disease Report
Patients & Caregivers


The FDA accepted a supplemental New Drug Application and granted Priority Review for Zelboraf, a therapy for Erdheim-Chester disease with a BRAF V600 mutation.
TheFDA has approved Imbruvica (ibrutinib) for treating adults with chronic graft versus host disease (cGVHD) after failure of one or more treatments.
The FDA approved Idhifa (enasidenib) for treating patients with relapsed or refractory AML who have mutations in their IDH2 gene.
This Saturday, proceeds from shopping on QVC will go towards Ovarian Cancer Research Fund Alliance (OCRFA).
Proceeds from the sales will go to St. Jude Children's Research Hospital and the Epidermolysis Bullosa Medical Research Foundation.
Just 10 days after undergoing surgery to remove a tumor in his brain, Arizona Senator John McCain is back at work in Washington D.C.
Pediatric MATCH is enrolling children and adolescents with solid tumors who have progressed either during or after standard therapy.
Glioblastoma is the same type of cancer that the late Senator Ted Kennedy had.
Adults with relapsed or refractory ALL generally have a poor prognosis with a median survival time of 3 to 5 months.
The emperor often talked about cancer and prior to his death, he demanded an autopsy be performed and his stomach be examined.
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.